Magnesium and Cramping

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-29

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hysteroscopy (an exam to look inside the uterus) is one of the most frequently performed procedures for patients with cervical or uterine disorders. It is the gold standard for evaluating various intrauterine problems, pre-menopausal and post-menopausal abnormal uterine bleeding, as well as being a vital examination modality for infertility work-up. Although hysteroscopy is a minimally invasive procedure, it is still known to be a painful experience that requires effective analgesia (meaning pain reduction) to achieve maximum patient comfort and cooperation. Historically, opioids, particularly fentanyl, have held precedence as the primary agents for providing analgesia following surgery of this type. However, despite their efficacy, these agents come with notable drawbacks, including the potential for serious side effects such as respiratory depression, addiction, and postoperative nausea and vomiting.

Both magnesium and ketamine are routinely used to reduce pain following this procedure. Both drugs work on the N-methyl-D-aspartate (NMDA) receptor in the brain to reduce pain, and magnesium has an additional effect in that it can relax smooth muscles. Magnesium has been used successfully to reduce the pain associated with menstrual cramps, which is similar to the pain patients experience after hysteroscopy.

A recent study demonstrated the benefits of adding intravenous magnesium with routine anesthesia during hysteroscopy, revealing a significant decrease in postoperative pain and rescue analgesics. However, this study did not compare the effects of magnesium to ketamine, nor did they characterize the nature of the patients' pain. It is unclear if the pain reduction with magnesium comes from its effect on the NMDA receptor or from it's cramp-reduction effect. We seek to establish whether administering IV magnesium, compared to ketamine, can specifically mitigate uterine cramping pain and total opioid consumption in hopes of finding additional safe and effective pain modalities for patients.

This is a prospective, randomized trial enrolling participants undergoing an elective hysteroscopy or Dilation and Curettage (D\&C) at Corewell Health William Beaumont University Hospital in Royal Oak. Participants will be randomized to 1 of 3 treatments: Intravenous (IV) Magnesium, IV Push Ketamine, or Placebo. Opioid consumption is recorded via the electronic medical record (EMR), while overall pain and cramping pain will be captured post-procedure in the hospital and 24 hours later via a phone call.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of Antinociceptive Effects of Ketamine and Magnesium Used for Sedation in Hysteroscopy Cases

NCT06739460

Hysteroscopy

ENROLLING_BY_INVITATION

Intraperitoneal Bupivacaine With Magnesium or Nalbuphine for Postoperative Pain Control in Laparoscopic Hysterectomy

NCT03393572

Anesthesia

COMPLETED PHASE4

Lidocaine and Ketamine in Abdominal Surgery

NCT00721110

Abdominal Hysterectomy (& Wertheim)

TERMINATED NA

Intra-operative Uterosacral Ligament Bupivacaine Injection During Minimally Invasive Hysterectomy

NCT04157075

Pain, Postoperative Opioid Use

COMPLETED EARLY_PHASE1

Magnesium-Based Trigger Point Injections for Relief of Chronic Myofascial Pelvic Pain

NCT02728037

Pelvic Pain

TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, randomized trial enrolling participants undergoing an elective hysteroscopy or Dilation and Curettage (D\&C) at Corewell Health William Beaumont University Hospital in Royal Oak. Participants will be initially contact via phone call 1 week prior to the procedure. If interested in participating, the study will be discussed pre-operatively and consent will be obtained. Baseline data including demographics, gynecological medical and surgical history, social history, allergies, current medications, ASA status, diagnosis, treatment and paucity will be collected.

The participant will be randomized to one of three study arms: IV magnesium, IV push ketamine, or placebo. The participants and evaluators will be blinded to the assigned study arm. The Principal Investigator and Anesthesiologist will not be blinded. All participants will receive standard of care anesthesia care and standard of care for the procedure.

Post-procedure, participants will receive standard of care pain management. Opioid consumption documented in the EMR will be recorded, and pain post-procedure pain will be assessed. Overall pain and cramping pain will be assessed using the Visual Analog Scale (VAS) at 1 hour, 2 hours, and 24 hours post procedure. The 24 hour pain assessment will be completed via phone.

Adverse events will be monitored for 24 hours post operatively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Uterine Cramps Postoperative Pain Management Hysteroscopy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Magnesium, IV

Intravenous magnesium 2 grams given over 20 minutes intra-operatively

Group Type EXPERIMENTAL

Magnesium sulfate

Intervention Type DRUG

Receive intravenous magnesium intra-operatively

Ketamine, IV

Intravenous ketamine 0.5 milligrams per kilogram dosed to ideal bodyweight, IV push intra-operatively

Group Type EXPERIMENTAL

Ketamine

Intervention Type DRUG

Receive IV push ketamine intra-operatively

Placebo

No administration of placebo infusion, ketamine or magnesium intra-operatively

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Receives no additional medication or infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium sulfate

Receive intravenous magnesium intra-operatively

Intervention Type DRUG

Ketamine

Receive IV push ketamine intra-operatively

Intervention Type DRUG

Placebo

Receives no additional medication or infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients undergoing an elective hysteroscopy or dilation and curettage (D\&C)
* American Society of Anesthesiologists (ASA) Physical Status 1 - 3
* Age 18 years or older

Exclusion Criteria

* Chronic Pain Patients (taking opioids within one week of procedure)
* Psychiatric Disorders (current treatment for anxiety/depression)
* Allergies to any of the medications that will be administered
* Current use of magnesium, analgesics, antidepressants, anxiolytics, or opioids
* ASA Physical Status 4 or above
* Developmentally delayed patients that would not be able to verbalize pain scores
* Minors (under 18 years of age)
* Pregnant women

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No